Nearly half of patients with metastatic castration-resistant prostate cancer harboring BRCA1/2 alterations do not receive PARP inhibitors, a new study finds.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/many-metastatic-prostate-cancer-not-receiving-parp-2025a1000que?src=rss
Author :
Publish date : 2025-10-06 18:42:00
Copyright for syndicated content belongs to the linked Source.